Burosumab, a monoclonal antibody targeted against FGF-23 and approved for TIO and X-linked hypophosphatemia (XLH), has not been extensively studied in patients with chronic kidney disease (CKD) and elevated FGF-23 levels. Here, FGF23 is linked to chronic kidney disease.